Harbor Capital Advisors, Inc. Blueprint Medicines Corp Transaction History

Harbor Capital Advisors, Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 09, 2024	SELL	$85.18 - $108.78 $255,454 - $326,231	-2,999 Reduced 11.12%	23,978 $2.58 Million
Q1 2024 May 13, 2024	SELL	$73.17 - $99.79 $258,729 - $352,857	-3,536 Reduced 11.59%	26,977 $2.56 Million
Q4 2023 Jan 08, 2024	SELL	$43.96 - $92.84 $86,645 - $182,987	-1,971 Reduced 6.07%	30,513 $2.81 Million
Q3 2023 Oct 20, 2023	BUY	$46.9 - $66.0 $381,343 - $536,646	8,131 Added 33.39%	32,484 $1.63 Million
Q2 2023 Jul 11, 2023	BUY	$42.2 - $66.37 $1.03 Million - $1.62 Million	24,353 New	24,353 $1.54 Million
Q3 2022 Oct 28, 2022	SELL	$49.93 - $77.7 $387,456 - $602,952	-7,760 Reduced 62.91%	4,575 $301,000
Q2 2022 Jul 26, 2022	SELL	$45.23 - $70.15 $6,920 - $10,732	-153 Reduced 1.23%	12,335 $623,000
Q1 2022 Apr 28, 2022	SELL	$54.1 - $110.08 $98,786 - $201,006	-1,826 Reduced 12.76%	12,488 $798,000
Q4 2021 Feb 04, 2022	BUY	$94.25 - $115.99 $1.35 Million - $1.66 Million	14,314 New	14,314 $1.53 Million

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.47B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Harbor Capital Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Harbor Capital Advisors, Inc. with notifications on news.